Portfolio company Radar Therapeutics raised $13.4M in seed funding to develop smart programmable medicines using molecular RNA sensors.
Radar Therapeutics is pioneering a new treatment modality: precision-expressed mRNA-based therapeutics
Radar Therapeutics is pioneering a new treatment modality: precision-expressed mRNA-based therapeutics. The company leverages advances in single-cell transcriptomic data and RNA-editing enzymes to create 'smart' mRNAs that can read the information a cell has to offer in real time, allowing for precise targeting of therapies.